# Notice of Allowability

Application No.	Applicant(s)
10/561,018	COTARCA ET AL.
Examiner	Art Unit
KARL J. PUTTLITZ	1621

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address-All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included
herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS
NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative
of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

- 1. This communication is responsive to interview of 3/7/2008 and examiner's amendment of 3/10/2008.
- The allowed claim(s) is/are 1-5.
- 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☑ All b) ☐ Some\* c) ☐ None of the:
    - 1. \( \subseteq \text{ Certified copies of the priority documents have been received.} \)
    - Certified copies of the priority documents have been received in Application No.
      - Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
  - \* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

- A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
- 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1) Thereto or 2) to Paper No./Mail Date
  - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

## Attachment(s)

- 1. | Notice of References Cited (PTO-892)
- 2. Notice of Draftperson's Patent Drawing Review (PTO-948)
- Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date
- Examiner's Comment Regarding Requirement for Deposit of Biological Material
- 5. Notice of Informal Patent Application
- 6. Interview Summary (PTO-413),
- Paper No./Mail Date <u>attached</u>.

  7. 
  Examiner's Amendment/Comment
- 8. X Examiner's Statement of Reasons for Allowance
- 9. 🔲 Other \_\_\_\_\_.

Application/Control Number: 10/561,018

Art Unit: 1621

# REASONS FOR ALLOWANCE

#### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Richard Chinn on 3/10/2008:

In the specification, at page 1, line 3, replace "anti-epilectic" with "anti-epileptic".

The following is an examiner's statement of reasons for allowance:

The outstanding prior art rejection is withdrawn since neither of the applied references teach the combined use of ammonia and alkaline hydroxide as eluting agents. Moreover, the applied references fail to provide a basis for modifying their disclosures to include the combined use of ammonia and alkaline hydroxide as eluting agents.

The double patenting rejection over 11/390451 is withdrawn since the claims of that application fail to recite the combined use of ammonia and alkaline hydroxide as eluting agents. Moreover, the claims of 11/390451 fail to provide a basis for modifying their scope to include ammonia and alkaline hydroxide as eluting agents.

The double patenting rejection over 10/582790 is withdrawn in view of the Terminal Disclaimer Application/Control Number: 10/561,018

Art Unit: 1621

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karl J. Puttlitz whose telephone number is (571) 272-0645. The examiner can normally be reached on Monday to Friday from 9 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached at telephone number (571) 272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Karl J. Puttlitz/

Primary Examiner, Art Unit 1621